AMWILL.BO · BSE
Amwill Health Care Limited
₹44.48
-0.16% (-₹0.07)
Prev. close
₹44.55
Volume
13,200
As of
23 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Amwill Health Care Limited
Amwill Health Care Limited, a derma-cosmetic company, engages in the development and contract manufacturing of generic dermatological solutions in India. It offers product formulations for anti-acne, dry skin, anti-aging, anti-fungal, anti-histaminic, anti-perspirant, antibiotics, skin lightening, hair care, steroid and keratolytic, sunscreen, vitiligo, miscellaneous, peri-orbital hyperpigmentation, anti-scar, topical antibiotics, antioxidants, and anti-scabies, as well as cosmeceutical and aesthetic categories. The company was founded in 2009 and is headquartered in Bengaluru, India.
Details
Sector
Healthcare
Industry
Medical Distribution
CEO
Mr. Tarun Gandhi
Headquarters
Bengaluru
Website
amwillhealthcare.comExchange
View on BSE ↗Key stats
Market cap
₹88.98 Cr
P/E ratio (TTM)
7.8
Dividend yield
1.12%
EPS (TTM)
₹5.71
Beta (1Y · daily vs NIFTY 50)
0.96
Shares float
41.32 L
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: Yahoo (no NSE corporate-actions ledger for this listing).
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹30.17 Cr | ₹43.95 Cr | ₹40.58 Cr | ₹45.49 Cr | |
| EBITDA | — | ₹4.39 Cr | ₹16.71 Cr | ₹11.78 Cr | ₹13.10 Cr |
| — | ₹3.11 Cr | ₹12.50 Cr | ₹10.73 Cr | ₹11.42 Cr | |
| Diluted EPS | ₹1.29 | ₹1.56 | ₹6.25 | ₹6.63 | ₹5.71 |
Revenue, Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, EBITDA, Net income, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
EBITDA for Mar 2026 could not be independently verified against the company's own annual report: this page shows ₹13.10 Cr while the annual report gives ₹15.91 Cr (21.4% apart).
09 · Balance Sheet
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹12.39 Cr | ₹18.98 Cr | ₹71.48 Cr | ₹86.67 Cr | |
| ₹12.11 L | ₹3.50 L | ₹0 | — | — | |
| Stockholders' equity | — | ₹4.60 Cr | ₹17.16 Cr | ₹69.22 Cr | ₹80.58 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹4.79 Cr | ₹-3.06 Cr | ₹5.56 Cr | ₹8.00 Cr | |
| Investing cash flow | — | ₹-1.27 Cr | ₹-1.39 Cr | ₹-46.22 Cr | ₹5.56 Cr |
| — | ₹-8.60 L | ₹-1.50 L | ₹41.33 Cr | ₹-5.86 L | |
| Capital expenditure | — | ₹-31.47 L | ₹-89.13 L | ₹-71.58 L | ₹-58.48 L |
| End cash position | — | ₹5.84 Cr | ₹1.38 Cr | ₹2.06 Cr | ₹15.56 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.48 L Cr | ₹9,624 | 84.9 | 14.81 | 15.3% | 0.00 | +12.3% | +59.0% |
| Torrent Pharmaceuticals Limited | ₹1.88 L Cr | ₹4,985 | 78.8 | 22.38 | 25.8% | 1.79 | +21.5% | +36.5% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.20 L Cr | ₹686.7 | 181.0 | 13.70 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,170.1 | 25.9 | 4.28 | 18.6% | 0.46 | +18.4% | +12.0% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,034 | 99.7 | 20.52 | 16.8% | 0.48 | +22.0% | +123.5% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,211.2 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.4% |
| Manipal Health Enterprises Limited | ₹99,126.82 Cr | ₹760.95 | 150.7 | 11.76 | 7.8% | 1.53 | +18.0% | — |
| Amwill Health Care Limited | ₹89.12 Cr | ₹44.55 | 7.8 | 1.11 | 14.2% | — | +12.1% | -23.0% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Amwill Health Care Limited Approves A Final Dividend for the Financial Year Ended March 31, 2026
Amwill Health Care Limited's 9th Annual General Meeting approved a final dividend of INR 0.50 per equity share for the financial year ended March 31, 2026. This dividend is based on a face value of INR 10 per share.